Iteos Therapeutics Stock News

The stock is about to become a component of a high-profile index.

ITeos Therapeutics Inc (ITOS) shares closed today at 1.4% below its 52 week high of $47.61, giving the company a market cap of $1B. The stock is currently up 38.7% year-to-date, up 40.7% over the past 12 months, and up 146.3% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 28.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -235.1% The company's stock price performance over the past 12 months beats the peer average by -234.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Related Stocks: ITOS ,

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the target of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 460,000 shares, a decrease of 27.8% from the November 15th total of 636,900 shares. Approximately 1.7% of the shares of the company are short sold. Based on []

iTeos Therapeutics, Inc. (NASDAQ:ITOS) insider Joanne Jenkins Lager sold 7,000 shares of the stock in a transaction dated Friday, December 17th. The stock was sold at an average price of $41.00, for a total transaction of $287,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Joanne []

iTeos Therapeutics (NASDAQ:ITOS) had its price objective lifted by HC Wainwright from $37.00 to $54.00 in a research report report published on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. Several other brokerages have also recently issued reports on ITOS. Zacks Investment Research cut iTeos Therapeutics from a []

Wall Street brokerages expect iTeos Therapeutics, Inc. (NASDAQ:ITOS) to report $1.28 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for iTeos Therapeutics’ earnings, with the highest EPS estimate coming in at $1.84 and the lowest estimate coming in at $0.69. iTeos Therapeutics posted earnings per […]

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Bioventures 2018 L.P. Mpm sold 20,167 shares of the firms stock in a transaction dated Friday, December 3rd. The shares were sold at an average price of $34.79, for a total value of $701,609.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is []

Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in combinat

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the presentation of new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021 .

iTeos Therapeutics, Inc. (NASDAQ:ITOS) gapped up prior to trading on Tuesday . The stock had previously closed at $32.16, but opened at $34.58. iTeos Therapeutics shares last traded at $34.85, with a volume of 378 shares. Several research analysts have commented on ITOS shares. Zacks Investment Research downgraded iTeos Therapeutics from a “buy” rating to […]

iTeos Therapeutics (NASDAQ:ITOS) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Earnings & Valuation This table compares iTeos Therapeutics and AlloVirs revenue, earnings per share and valuation. []

Zacks Investment Research upgraded shares of iTeos Therapeutics (NASDAQ:ITOS) from a hold rating to a buy rating in a report published on Thursday, Zacks.com reports. The brokerage currently has $41.00 price target on the stock. According to Zacks, iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology [] The post iTeos Therapeutics (NASDAQ:ITOS) Lifted to Buy at Zacks Investment Research appeared first on ETF Daily News .

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was down 3.8% during mid-day trading on Wednesday after an insider sold shares in the company. The company traded as low as $34.82 and last traded at $35.03. Approximately 4,380 shares traded hands during trading, a decline of 99% from the average daily volume of 301,339 shares. The stock had previously []

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Ansbert Gadicke sold 35,333 shares of the businesss stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $37.52, for a total value of $1,325,694.16. The sale was disclosed in a filing with the SEC, which is accessible through this []